CD4 and rheumatoid arthritis: In established previously treated RA patients, circulating proportions of CD4+ T cells, including TFh, T regulatory (Treg), and CXCR3+ Th17 cells, have been reported to predict therapeutic response to CTLA-4Ig treatment after 24 weeks [11–13].